Subtitles are available in English and other languages. They are automatically generated using AI, so some errors may occur.
PCR meets China: great innovations and novel trials
Stents, scaffolds and DCB
Other valvular and structural interventions
Hotline / Late-Breaking Trials
Room 242AB
Anchorperson: Bernard Prendergast
Spokesperson: William Wijns
Discussants: Kefei Dou, Elvin Kedhi, Jianfang Luo, Shengxian Tu
Watch this session if you want
- To learn about clinically relevant innovations developed in China both for coronary and valvular indications
- To recognise the potential impact and global outreach of domestic device development
- To exchange with the Chinese colleagues attending EuroPCR 2025 and celebrate our long-lasting collaboration
Welcome and session objectives
Bernard Prendergast
Angiography-based RWS in predicting non-target vessel failure at five-year: blinded post-hoc analysis of the target all comers randomised trial
Jiayue Huang
Discussion and audience interaction
Does incremental information regarding coronary physiology and plaque vulnerability influence revascularisation decisions
Daixin Ding
Discussion and audience interaction
Robotic PCI: clinical progress and practice of China
Yundai Chen
Discussion and audience interaction
Safety and efficacy of the Neonova TEER system in degenerative mitral regurgitation: a multicentre prospective study
Yan Wang
Discussion and audience interaction
TAVR with a fully retrievable self-expanding dry-tissue valve: one-year results of the first-in-man study
Zhengang Zhao
Discussion and audience interaction
Session evaluation and key learnings
William Wijns
